| Targol Saedi, MD | |
|
3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 | |
| (503) 494-6101 | |
| (503) 494-1159 |
| Full Name | Targol Saedi |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 17 Years |
| Location | 3181 Sw Sam Jackson Park Rd, Portland, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396919874 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 154448 (Oregon) | Primary |
| 207R00000X | Internal Medicine | 154448 (Oregon) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
News Archive
A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.
Cadent, the leading provider of 3-D digital and CAD/CAM solutions for orthodontics and dentistry, announced that it finalized an agreement last month with The Straumann Group, a global leader in regenerative, restorative and replacement dentistry, whereby Straumann will become the exclusive European distributor of the iTero digital impressions system.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
ArtVentive Medical Group, Inc. announced today that the Company has frozen its Endoluminal Occlusion device design for the peripheral category of indications in preparation for the Company's regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
› Verified 2 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.
Cadent, the leading provider of 3-D digital and CAD/CAM solutions for orthodontics and dentistry, announced that it finalized an agreement last month with The Straumann Group, a global leader in regenerative, restorative and replacement dentistry, whereby Straumann will become the exclusive European distributor of the iTero digital impressions system.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
ArtVentive Medical Group, Inc. announced today that the Company has frozen its Endoluminal Occlusion device design for the peripheral category of indications in preparation for the Company's regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
› Verified 2 days ago
| Entity Name | Portland Adventist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750091021 PECOS PAC ID: 3274908819 Enrollment ID: O20230412001327 |
News Archive
A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.
Cadent, the leading provider of 3-D digital and CAD/CAM solutions for orthodontics and dentistry, announced that it finalized an agreement last month with The Straumann Group, a global leader in regenerative, restorative and replacement dentistry, whereby Straumann will become the exclusive European distributor of the iTero digital impressions system.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
ArtVentive Medical Group, Inc. announced today that the Company has frozen its Endoluminal Occlusion device design for the peripheral category of indications in preparation for the Company's regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Targol Saedi, MD 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 494-6101 | Targol Saedi, MD 3181 Sw Sam Jackson Park Rd, Portland, OR 97239-3011 Ph: (503) 494-6101 |
News Archive
A new Australian prostate cancer clinical trial hopes to provide clear evidence to men with prostate cancer about the best time to start hormone treatment in terms of prolonging life, balanced against the effects on their quality of life.
Cadent, the leading provider of 3-D digital and CAD/CAM solutions for orthodontics and dentistry, announced that it finalized an agreement last month with The Straumann Group, a global leader in regenerative, restorative and replacement dentistry, whereby Straumann will become the exclusive European distributor of the iTero digital impressions system.
The first randomized Phase II clinical trial to report on single and combined neoadjuvant immune checkpoint inhibitor therapy in stage I-III non-small cell lung cancer (NSCLC) found combination therapy produced a significant clinical benefit, as assessed by major pathologic response (MPR) rate, as well as enhanced tumor immune cell infiltration and immunological memory.
ArtVentive Medical Group, Inc. announced today that the Company has frozen its Endoluminal Occlusion device design for the peripheral category of indications in preparation for the Company's regulatory phase, prior to commercialization in Europe and North America and subsequent to venturing forward into Eastern Europe, Japan, Asia Pacific and Latin America.
› Verified 2 days ago
Ellen B Stevenson, MD Hospitalist Medicare: Medicare Enrolled Practice Location: 2801 N Gantenbein Ave, Department Of Pediatrics, Legacy Emanuel Hospital, Portland, OR 97227 Phone: 503-413-2402 Fax: 503-413-2566 | |
Ivan I Biley, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Mt 2800, Portland, OR 97225 Phone: 503-216-2621 | |
Dr. Thomas G Wimmer, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 Fax: 503-216-4114 | |
Dr. Rhonda Ann Brown, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 4400 Ne Halsey St, Portland, OR 97213 Phone: 503-215-0750 | |
Todd R Merrick, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 9205 Sw Barnes Rd, Portland, OR 97225 Phone: 503-216-2906 Fax: 503-216-4114 | |
Dr. Rachel Anne Westwood, MD Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd # L-579, Portland, OR 97239 Phone: 503-494-8311 | |
Joel N Papak, M.D. Hospitalist Medicare: Not Enrolled in Medicare Practice Location: 3710 Sw Us Veterans Hospital Rd, P3med, Portland, OR 97239 Phone: 503-220-8262 |